Treatment of vitiligo with narrow-band ultraviolet B: advantages and disadvantages.

J Cutan Med Surg

Undergraduates Studies, Faculty of Medicine, Division of Dermatology, University of Ottawa, Ottawa, ON.

Published: December 2008

Background: Narrow-band ultraviolet B (NB-UVB) therapy for vitiligo is increasingly used in patients who are unresponsive to other forms of therapy.

Objective: This study measures levels of patient and physician satisfaction and the associated advantages and disadvantages of NB-UVB.

Methods: A retrospective chart review was conducted of the first 50 patients with vitiligo treated at the Photoderm Clinic in Ottawa, Ontario. Data were obtained from digital photographs and patient charts (n = 50).

Results: Percent repigmentation of the face and body was very good compared with the hands and feet (poor = 0-or< 33%; good = 33-or< 66%; very good = >or= 66%). The physician and patients were satisfied with results achieved with NB-UVB therapy (very good [VG]: medical doctor [MD] 49% [95% CI 35-63], patient [Pt] 51% [95% CI 37-65]; good [G]: MD 24% [95% CI 12-36], Pt 22% [95% CI 10-34]).

Conclusion: NB-UVB therapy is an effective treatment for vitiligo (ie, VG, repigmentation >or= 66%) that leads to high levels of patient and physician treatment-related satisfaction. Although there are disadvantages to NB-UVB therapy, the advantages outweigh the drawbacks. An objective evaluation such as the Vitiligo Area Scoring Index (VASI) is necessary to validate these findings. Additional limitations include those inherent in retrospective study design.

Download full-text PDF

Source
http://dx.doi.org/10.2310/7750.2008.07054DOI Listing

Publication Analysis

Top Keywords

nb-uvb therapy
16
treatment vitiligo
8
narrow-band ultraviolet
8
advantages disadvantages
8
levels patient
8
patient physician
8
>or= 66%
8
good
5
vitiligo narrow-band
4
ultraviolet advantages
4

Similar Publications

Psoriasis is a chronic inflammatory skin condition characterized by hyperproliferation of keratinocytes and immune dysregulation. Narrow band ultraviolet B (NB-UVB) phototherapy is a common treatment for psoriasis due to its efficacy and safety profile. NOD2 is an intracellular pattern recognition receptor involved in immune responses and inflammation, and its expression is elevated in psoriatic skin.

View Article and Find Full Text PDF

Vitiligo is a chronic depigmenting condition that causes amelanotic macules and patches on the skin. Despite various treatment options, treating vitiligo is a challenge. This study aimed to evaluate the combination of laser CO fractional and narrow-band ultraviolet B (NB-UVB) versus NB-UVB monotherapy in vitiligo patients.

View Article and Find Full Text PDF

Background: Vitiligo is a chronic autoimmune disease manifested by depigmented patches of skin devoid of melanocytes. Baricitinib, a JAK inhibitor selectively targeting JAK1/2, has shown preliminary efficacy for vitiligo. We aimed to assess the efficacy and tolerability of combination therapy with baricitinib and narrowband UV-B (NB-UVB) to treat active nonsegmental vitiligo (NSV).

View Article and Find Full Text PDF

New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination.

SAGE Open Med Case Rep

December 2024

Department of Dermatology, College of Medicine, University of Saskatchewan, Regina, SK, Canada.

We report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This report adds to the growing evidence of new-onset LP following COVID-19 vaccination and underscores the need for careful reporting, monitoring, and management of vaccine-related adverse effects.

View Article and Find Full Text PDF

Chronic spontaneous urticaria (CSU) is defined as the occurrence of hives, angioedema, or both, lasting for more than 6 weeks. The treatment is based on the use of antihistamines, omalizumab, and/or cyclosporine following a stepwise algorithm recommended by international guidelines with a high level of evidence. Nevertheless, management can be challenging as some patients do not respond to the suggested drugs or have difficulties accessing them for various reasons.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!